ArticleHealth science reports2026
Global Burden of Premenstrual Syndrome and Uterine Fibroids in Women of Reproductive Age (1990-2023) and Projections to 2050: An Analysis of the Global Burden of Disease Study 2023.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Premenstrual syndrome (PMS) and uterine fibroids (UF) are major gynecological diseases that markedly affect the reproductive health of women of reproductive age (WRA). This study aimed to provide updated global estimates of these disorders among WRA (15-49 years) between 1990 and 2023 and to forecast future trends. Methods: Data from the GBD 2023 were used to assess the temporal trend and future projections of PMS and UF among WRA. Estimated annual percent change (EAPC), ARIMA model, and Pearson correlation analysis were used to assess temporal trends (1990-2023), forecast projections (2024-2050), and examine the association of socio-demographic index (SDI) with major gynecological disorders, respectively. Results: In 2023, the global incidence was approximately 233,405,777 cases of PMS and 10,017,494 cases of UF. Between 1990 and 2023, the age-standardized prevalence rates of PMS and UF among WRA increased, with EAPC of 0.06% (95% CI: 0.04, 0.07) and 0.58% (95% CI: 0.53, 0.62), and the corresponding age-standardized disability-adjusted life years (DALYs) rates also increased, with EAPC of 0.05% (95% CI: 0.03, 0.07) and 1.21% (95% CI: 1.01, 1.42), respectively. Projections to 2050 indicate a slight decline in PMS prevalence rates but a mild increase in DALY rates, whereas both the prevalence and DALY rates of UF are expected to rise substantially. The burden and temporal patterns of PMS and UF varied markedly across countries, regions, and SDI levels. The prevalence rates of PMS (r = 0.351) and UF (r = 0.381) showed significant positive correlations with SDI ( Conclusion: The global burden of PMS and UF has increased over the last 34 years, underscoring the need for targeted public health strategies to improve reproductive health in women.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.